ArticleFrontiers in oncology2026
Case Report: staged electron beam radiotherapy for inoperable primary ectopic abdominal extramammary Paget disease.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extramammary Paget disease (EMPD) is a rare cutaneous adenocarcinoma that usually arises in apocrine gland-bearing areas, whereas primary ectopic EMPD of the abdominal skin is exceptionally uncommon. We report a 79-year-old woman with a five-year history of progressively enlarging eczema-like lower abdominal-pelvic skin lesions, including erosion, exudation, scaling, crusting, and pruritus, initially treated as chronic dermatitis without improvement. Histopathology showed large atypical Paget cells with focal dermal microinvasion; immunohistochemistry was positive for cytokeratin 7 (CK7) and GATA-binding protein 3 (GATA3) and negative for cytokeratin 20 (CK20) and p40, while Ki-67, a proliferation marker, showed a labeling index of approximately 60%. Because radical surgery was unsuitable, she received response-adapted two-stage electron beam radiotherapy. The first stage delivered 43.2 Gy in 12 every-other-day fractions using 12-MeV electrons, a 5-mm tissue-equivalent bolus, and customized lead shielding, followed by a 10 Gy boost in five daily fractions using 9-MeV electrons for residual visible disease. The treated field showed complete clinical resolution approximately one month after radiotherapy, with no in-field recurrence nearly one year later. Residual erythematous scaly plaques persisted outside the original field. This case supports response-adapted electron beam radiotherapy as a feasible non-surgical option for selected inoperable superficial EMPD and emphasizes the practical importance of pretreatment mapping, adequate field coverage, bolus conformity, shielding, and field-edge planning for extensive lesions on curved body surfaces.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.